Vivacta Biotechnology
Develops in vivo CAR-T cell therapies for cancer and autoimmune diseases
$50MSeries A+
Role not disclosedAC
Apricot Capital
Activity from announced rounds
Activity in this selectionSeries A
- Rounds participated in
- 3
- Confirmed lead rounds
- — 3 roles undisclosed
- New companies
- 3 First participation on record · 0 follow-on
- Funding in participating rounds
- $165M 3 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
3 in this selectionVivatides Therapeutics
Develops extrahepatic RNA-targeting therapeutics
$54MSeries A
Role not disclosedVibrant Therapeutics
Develops intelligent, logic-gated therapeutics for solid tumors
$61MSeries A
Role not disclosed